Advanced search
1 file | 6.33 MB
Author
Organization
Abstract
Skeletal deformity and bone fragility are the hallmarks of the brittle bone dysplasia osteogenesis imperfecta. The diagnosis of osteogenesis imperfecta usually depends on family history and clinical presentation characterized by a fracture (or fractures) during the prenatal period, at birth or in early childhood; genetic tests can confirm diagnosis. Osteogenesis imperfecta is caused by dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 85% of individuals, affecting collagen quantity or structure. In the past decade, (mostly) recessive, dominant and X-linked defects in a wide variety of genes encoding proteins involved in type I collagen synthesis, processing, secretion and post-translational modification, as well as in proteins that regulate the differentiation and activity of bone-forming cells have been shown to cause osteogenesis imperfecta. The large number of causative genes has complicated the classic classification of the disease, and although a new genetic classification system is widely used, it is still debated. Phenotypic manifestations in many organs, in addition to bone, are reported, such as abnormalities in the cardiovascular and pulmonary systems, skin fragility, muscle weakness, hearing loss and dentinogenesis imperfecta. Management involves surgical and medical treatment of skeletal abnormalities, and treatment of other complications. More innovative approaches based on gene and cell therapy, and signalling pathway alterations, are under investigation.
Keywords
QUALITY-OF-LIFE, BONE MORPHOGENETIC PROTEIN-1, EHLERS-DANLOS-SYNDROME, INTRAVENOUS PAMIDRONATE THERAPY, GENOTYPE-PHENOTYPE CORRELATIONS, SCLEROSTIN ANTIBODY TREATMENT, PLACEBO-CONTROLLED TRIAL, GROWTH-FACTOR-BETA, MOUSE MODEL, I COLLAGEN

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 6.33 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Marini, Joan C, Antonella Forlino, Hans Peter Bachinger, Nick J Bishop, Peter H Byers, Anne De Paepe, Francois Fassier, et al. 2017. “Osteogenesis Imperfecta.” Nature Reviews Disease Primers 3.
APA
Marini, J. C., Forlino, A., Bachinger, H. P., Bishop, N. J., Byers, P. H., De Paepe, A., Fassier, F., et al. (2017). Osteogenesis imperfecta. NATURE REVIEWS DISEASE PRIMERS, 3.
Vancouver
1.
Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, De Paepe A, et al. Osteogenesis imperfecta. NATURE REVIEWS DISEASE PRIMERS. 2017;3.
MLA
Marini, Joan C, Antonella Forlino, Hans Peter Bachinger, et al. “Osteogenesis Imperfecta.” NATURE REVIEWS DISEASE PRIMERS 3 (2017): n. pag. Print.
@article{8551685,
  abstract     = {Skeletal deformity and bone fragility are the hallmarks of the brittle bone dysplasia osteogenesis imperfecta. The diagnosis of osteogenesis imperfecta usually depends on family history and clinical presentation characterized by a fracture (or fractures) during the prenatal period, at birth or in early childhood; genetic tests can confirm diagnosis. Osteogenesis imperfecta is caused by dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 85\% of individuals, affecting collagen quantity or structure. In the past decade, (mostly) recessive, dominant and X-linked defects in a wide variety of genes encoding proteins involved in type I collagen synthesis, processing, secretion and post-translational modification, as well as in proteins that regulate the differentiation and activity of bone-forming cells have been shown to cause osteogenesis imperfecta. The large number of causative genes has complicated the classic classification of the disease, and although a new genetic classification system is widely used, it is still debated. Phenotypic manifestations in many organs, in addition to bone, are reported, such as abnormalities in the cardiovascular and pulmonary systems, skin fragility, muscle weakness, hearing loss and dentinogenesis imperfecta. Management involves surgical and medical treatment of skeletal abnormalities, and treatment of other complications. More innovative approaches based on gene and cell therapy, and signalling pathway alterations, are under investigation.},
  articleno    = {17052},
  author       = {Marini, Joan C and Forlino, Antonella and Bachinger, Hans Peter and Bishop, Nick J and Byers, Peter H and De Paepe, Anne and Fassier, Francois and Fratzl-Zelman, Nadja and Kozloff, Kenneth M and Krakow, Deborah and Montpetit, Kathleen and Semler, Oliver},
  issn         = {2056-676X},
  journal      = {NATURE REVIEWS DISEASE PRIMERS},
  keyword      = {QUALITY-OF-LIFE,BONE MORPHOGENETIC PROTEIN-1,EHLERS-DANLOS-SYNDROME,INTRAVENOUS PAMIDRONATE THERAPY,GENOTYPE-PHENOTYPE CORRELATIONS,SCLEROSTIN ANTIBODY TREATMENT,PLACEBO-CONTROLLED TRIAL,GROWTH-FACTOR-BETA,MOUSE MODEL,I COLLAGEN},
  language     = {eng},
  pages        = {19},
  title        = {Osteogenesis imperfecta},
  url          = {http://dx.doi.org/10.1038/nrdp.2017.52},
  volume       = {3},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: